Tandem Diabetes Care (TNDM) Set to Announce Quarterly Earnings on Thursday

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) will announce its earnings results after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.80) per share for the quarter. Tandem Diabetes Care has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Individual interested in participating in the company's earnings conference call can do so using this link.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.04). The business had revenue of $196.80 million during the quarter, compared to analyst estimates of $204.86 million. Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. On average, analysts expect Tandem Diabetes Care to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tandem Diabetes Care Stock Performance

TNDM stock traded up $0.44 during trading on Thursday, reaching $35.56. The company had a trading volume of 1,568,049 shares, compared to its average volume of 1,733,326. The firm has a 50-day simple moving average of $30.51 and a 200-day simple moving average of $25.18. The company has a market cap of $2.30 billion, a price-to-earnings ratio of -10.34 and a beta of 1.12. Tandem Diabetes Care has a twelve month low of $13.82 and a twelve month high of $40.74. The company has a debt-to-equity ratio of 0.91, a quick ratio of 3.02 and a current ratio of 3.83.

Analyst Ratings Changes

TNDM has been the subject of a number of research reports. Citigroup lifted their target price on Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a "neutral" rating in a report on Wednesday, April 3rd. StockNews.com raised shares of Tandem Diabetes Care from a "sell" rating to a "hold" rating in a report on Friday, April 19th. SVB Leerink raised shares of Tandem Diabetes Care from a "market perform" rating to an "outperform" rating and raised their price objective for the stock from $34.00 to $45.00 in a research note on Thursday. Finally, Stifel Nicolaus boosted their target price on shares of Tandem Diabetes Care from $37.00 to $40.00 and gave the company a "buy" rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Tandem Diabetes Care presently has an average rating of "Hold" and an average price target of $39.45.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.